Takeda inaugurates €100m German oral solid dose plant

Image: iStock/Fredex8

Takeda has completed a €100m ($112m) oral solid dosage production facility in Germany.

Construction of the 21,400 m2 plant was first announced in August 2014, and last week an inauguration ceremony took place at Takeda’s Oranienburg, Brandenburg site.

When operations begin at the ‘M3P3’ facility – expected by the end of the year – the plant will produce solid pill and capsule forms of the Japanese pharma firm’s product portfolio, including its gastroenterology drug Protonix (pantoprazole) and its depression treatment Trintellix (vortioxetine).

Several of the products to be made at the facility will be transferred from Takeda’s Osaka, Japan plant as part of the firm’s strategy to optimise its global manufacturing network. The Osaka plant is being transformed into a specialty manufacturing site for Leuplin, Takeda’s treatment for hormone-dependent diseases such as prostate cancer and premenopausal breast cancer.

“We continuously invest in our facilities to advance our technologies in order to ensure a stable supply of high-quality drug products to patients around the world,” Thomas Wozniewski, Global Manufacturing & Supply officer from Takeda said in a statement.

Total cost of construction was around €100m, with the state of Brandenburg and the German federal government contributing €23m in subsidies.

Related News

Goodbye to AstraZeneca exec (Image: WoodleyWonderWorks)

Second senior exit at AZ, and what's next for Takeda and Sanofi execs?

Image: iStock/dk_photos

Takeda breaks ground on $45m Ninlaro plant in Ireland

Image: iStock/masterSergeant

Takeda to build €40m Irish plant for global Ninlaro API supply

iStock/cosmin4000

Takeda overturns negative EU CHMP opinion for oral drug Ninlaro in ‘face-to-face’ appeal

iStock/BernardaSv

Takeda hands regulatory affairs work to PRA in new deal

Related Products

See more related products